Literature DB >> 10877214

Gene therapy for cancer: from the laboratory to the patient.

G Kouraklis1.   

Abstract

Gene therapy is a new form of therapeutic intervention with applications in many areas of medical treatment. There are still many technical difficulties to be overcome, but recent advances in the molecular and cellular biology of gene transfer have made it likely that gene therapy will soon start to play an increasing role in clinical practice and particularly in the treatment of cancer. The first clinical gene transfer in an approved protocol took place exactly 10 years ago, and it was for the transfer of gene-marked immune cells into patients with advanced cancer. Now there are 218 active clinical protocols in the United States, and they have involved over 2000 patients worldwide. Among the conditions and diseases for which gene transfer is being tried as treatment, cancer comes first with 130 clinical trials. Fundamental research in the mechanisms of cancer and the development of molecular biology tools are crucial for the success of the treatments in the future. The identification of tumor rejection antigens from a variety of cancers and the immune response that is defective in cancer patients are important topics for future studies. The evaluation of gene therapy combinations involving use of tumor suppressor genes and constructs that inactivate oncogenes is also another important area for future research. The future improvement of present viruses as well as the use of new viral vectors will likely expand the applicability and efficacy of gene therapy. During the next decade technological developments, particularly in the areas of gene delivery and cell transplantation, will be critical for the successful clinical practice of gene therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10877214     DOI: 10.1023/a:1005592309466

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  63 in total

1.  The N2-TIL human gene transfer clinical protocol.

Authors: 
Journal:  Hum Gene Ther       Date:  1990       Impact factor: 5.695

2.  Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53.

Authors:  J A Roth
Journal:  Hum Gene Ther       Date:  1996-05-01       Impact factor: 5.695

3.  Nondefective spleen necrosis virus-derived vectors define the upper size limit for packaging reticuloendotheliosis viruses.

Authors:  C Gélinas; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 4.  Progress in cancer gene therapy.

Authors:  G Kouraklis
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

Review 5.  Human gene therapy comes of age.

Authors:  A D Miller
Journal:  Nature       Date:  1992-06-11       Impact factor: 49.962

6.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1.

Authors:  B P Sorrentino; S J Brandt; D Bodine; M Gottesman; I Pastan; A Cline; A W Nienhuis
Journal:  Science       Date:  1992-07-03       Impact factor: 47.728

7.  Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.

Authors:  G R Peplinski; K Tsung; E D Whitman; J B Meko; J A Norton
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

Review 8.  A brief history of gene therapy.

Authors:  T Friedmann
Journal:  Nat Genet       Date:  1992-10       Impact factor: 38.330

9.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 10.  Transfer of genes to humans: early lessons and obstacles to success.

Authors:  R G Crystal
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

View more
  6 in total

1.  Gene therapy for cancer: current status and prospects.

Authors:  Gregory P Kouraklis
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

2.  Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.

Authors:  Lars Boenicke; Kang Chu; Regina Pauls; Claudia Tams; Marie-Luise Kruse; Roland Kurdow; Bodo Schniewind; Arnd Böhle; Bernd Kremer; Holger Kalthoff
Journal:  J Mol Med (Berl)       Date:  2003-03-18       Impact factor: 4.599

3.  Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.

Authors:  Kui Wang; Forrest M Kievit; Jonathan G Sham; Mike Jeon; Zachary R Stephen; Arvind Bakthavatsalam; James O Park; Miqin Zhang
Journal:  Small       Date:  2015-12-07       Impact factor: 13.281

4.  Transcriptional targeting of glioblastoma by diphtheria toxin-A driven by both H19 and IGF2-P4 promoters.

Authors:  Doron Amit; Imad J Matouk; Iris Lavon; Tatiana Birman; Jenifer Galula; Rasha Abu-Lail; Tamar Schneider; Tali Siegal; Abraham Hochberg; Yakov Fellig
Journal:  Int J Clin Exp Med       Date:  2012-04-06

5.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  J Transl Med       Date:  2010-12-16       Impact factor: 5.531

Review 6.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.